Integrated Analysis of Disulfidptosis-Related Genes Identifies CD2AP as a Potential Therapeutic Target for Hepatocellular Carcinoma
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26094454 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Ning Shang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gufu Dai, Xiaowen Guan, Henan Provincial Key Research and Development Special Project.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a deadly cancer with limited treatment options for patients at advanced stages. It is urgent to develop reliable prognostic risk models and identify more biomarkers to improve the clinical outcomes of patients with HCC. Disulfidptosis is a newly discovered form of regulated cell death (RCD), and research on the comprehensive roles of disulfidptosis-related genes (DRGs) in HCC prognosis and development remains limited. In this paper, we systematically analyzed the expression levels and prognostic profiles of 26 DRGs in HCC samples from The Cancer Genome Atlas (TCGA) cohort and developed a prognostic risk model using seven hub DRGs. The independent prognostic value of the risk model was further validated in the external cohort. The overall survival of patients with HCC in the low-risk group was significantly longer than that of those in the high-risk group. Subsequently, the protein level of CD2-associated protein (CD2AP) was found to be highly expressed in HCC clinical tissues and associated with the severity of HCC. In vitro experiments demonstrated that the down-regulation of CD2AP attenuated the proliferation, migration, invasion, and epithelial–mesenchymal transition (EMT) abilities of HCC cells. Taken together, our study revealed that the DRG CD2AP may serve as a potential biomarker for HCC and offer support for prognosis prediction of patients with HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China.
- School of Computer and Artificial Intelligence, Zhengzhou University, Zhengzhou 450001, China.
Förderung
- Gufu Dai
- Xiaowen Guan
- Henan Provincial Key Research and Development Special Project
- National Natural Science Foundation of China
Zitieren
APA
Shang, N., Wang, J., Liu, Z., Wang, Y., Zhang, D., Liu, H., Zhang, Y., Dai, G., & Guan, X. (2025). Integrated Analysis of Disulfidptosis-Related Genes Identifies CD2AP as a Potential Therapeutic Target for Hepatocellular Carcinoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26094454
Vancouver
Shang N, Wang J, Liu Z, Wang Y, Zhang D, Liu H, et al. Integrated Analysis of Disulfidptosis-Related Genes Identifies CD2AP as a Potential Therapeutic Target for Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26094454
BibTeX
@article{Shang2025,
author = {Shang, Ning and Wang, Jianwei and Liu, Zihan and Wang, Yake and Zhang, Di and Liu, Huanfei and Zhang, Yaqing and Dai, Guifu and Guan, Xiaowen},
title = {Integrated Analysis of Disulfidptosis-Related Genes Identifies CD2AP as a Potential Therapeutic Target for Hepatocellular Carcinoma},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26094454}
}
EUVIMED